Prediction of Biologic Aggressiveness in Human Meningiomas: A Cell Kinetic Study Using Bromodeoxy-uridine in Cells of Primary Explant Culture

Kharbanda, Kusum K.; Karak, Asis Kumar; Sarkar, Chitra; Dinda, Amit Kumar; Mathur, Meera; Roy, S. C. Dutta

doi:10.1093/jnci/84.3.194

Cited by 11 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation is of special interest in light of our earlier postulation that despite histologic homogeneity and 'benign' appearance, any meningioma in primary culture which shows an in vitro first week BrdU-LI of greater than 5% is likely to behave ag-gressively [8]. We believe that the group I type growth pattern in vitro may be another index for assessing the biological behaviour in cases of meningiomas, and suggest that the tumors which have this type of growth pattern, though they may appear histologically benign, should be carefully monitored clinically and perhaps treated more aggressively in order to prevent recurrence.…”

Section: Discussionmentioning

confidence: 91%

“…Reports on in vivo Bromodeoxyuridine labeling index (BrdU-LI) and proliferative index (PI) based on fluorescent flow cytometric analysis (DNA-FCM) of tissues in cases of meningiomas have been found to have a close correlation with clinically aggressive behaviour [4][5][6][7]. Recently, the in vitro BrdU-LI estimation at the end of first week in primary cultures of meningiomas has been shown to be on par [8] as an alternative to in vivo BrdU-LI [4,5] and DNA-FCM studies [6,7] for predicting the biological aggressiveness of these tumors irrespective of their histological homogeneity. Further, there are reports based on the DNA-FCM analysis which indicate that data obtained from primary cultures in meningiomas can provide equally valuable information for predicting biologic behaviour [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A sequential cell kinetic study of meningioma cells in primary explant culture using bromodeoxyuridine

et al. 1993

Self Cite

View full text Add to dashboard Cite

The present study was undertaken to evaluate the sequential BrdU-LI at weekly intervals upto four weeks in 18 primary explant cultures of meningiomas. This revealed three distinct patterns of growth which could be arbitrarily defined as 'degenerating' (group I), 'proliferating' (group II) and 'adaptive' (group III) types. Interestingly two cases of malignant and two of recurrent meningiomas fell into the 'degenerating' group I pattern. The possible explanations for the observed relatively higher in vitro LI values compared to lower in vivo values as reported in the literature and the theoretical implications of the three distinct patterns of sequential LI values are discussed.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

A sequential cell kinetic study of meningioma cells in primary explant culture using bromodeoxyuridine

et al. 1993

Self Cite

View full text Add to dashboard Cite

show abstract

The application of 5-bromodeoxyuridine in the management of CNS tumors

et al. 1994

View full text Add to dashboard Cite

A variety of clinical reports have described the application of the bromodeoxyuridine labeling index as an adjunct to conventional pathological examination of CNS tumors. This index has proven useful in predicting the clinical outcome associated with many such tumors. Furthermore, because of its efficacy as a radiosensitizing agent, bromodeoxyuridine (and the closely related iododeoxyuridine) has been used in combination with radiation therapy for malignant glial neoplasms, with some encouraging results. Although most studies suggest that bromodeoxyuridine is safe, there is evidence that this compound does have potential side-effects, including the observation that it is a mutagen and carcinogen in some experimental systems. A number of new alternative approaches for predicting the clinical outcome of CNS tumors has been developed based on an increased understanding of their molecular biology. However, until such approaches are better characterized, the clinical application of bromodeoxyuridine will continue to play an important role in predicting the clinical behavior of many CNS tumors.

show abstract

A correlative study ofin vivo andin vitro labeling index using bromodeoxyuridine in human brain tumors

et al. 1995

View full text Add to dashboard Cite

The labeling index (LI) of 216 cases of human brain tumors was determined by the immunohistochemical technique with monoclonal antibody to bromodeoxyuridine (BrdU). The proliferative potential of 110 cases was estimated using the intra-operative intravenous infusion of BrdU at a dose of 200 mg/sq m. In another 106 cases, the in vitro technique of incubating freshly resected tumor tissue fragments with 100 microM bromodeoxyuridine was used. The BrdU LI in these tumors was then correlated with the histological types and the data as determined by both the in vivo and in vitro BrdU incorporation were compared. The results indicate that although in vivo and in vitro techniques could possibly provide equivalent data in some histologic types, a clear statistically valid proof however is not apparent from this study.

show abstract

Prediction of Biologic Aggressiveness in Human Meningiomas: A Cell Kinetic Study Using Bromodeoxy-uridine in Cells of Primary Explant Culture

Cited by 11 publications

References 1 publication

A sequential cell kinetic study of meningioma cells in primary explant culture using bromodeoxyuridine

A sequential cell kinetic study of meningioma cells in primary explant culture using bromodeoxyuridine

The application of 5-bromodeoxyuridine in the management of CNS tumors

A correlative study ofin vivo andin vitro labeling index using bromodeoxyuridine in human brain tumors

Contact Info

Product

Resources

About